adebrelimab + dalpiciclib + letrozole

This is a combination therapy consisting of three agents: - **Adebrelimab** (a monoclonal antibody targeting PD-L1, used as an immune checkpoint inhibitor in oncology; not directly referenced in the provided search results for breast cancer but known from external sources to be under investigation for various cancers), - **Dalpiciclib** (a novel, oral cyclin-dependent kinase 4/6 [CDK4/6] inhibitor developed for hormone receptor-positive, HER2-negative breast cancer; it blocks cell cycle progression by inhibiting CDK4/6 activity[1][5]), - **Letrozole** (an oral nonsteroidal aromatase inhibitor that reduces estrogen production and is widely used as endocrine therapy in postmenopausal women with hormone receptor-positive breast cancer[5][6][8][10]). The combination of dalpiciclib and letrozole has demonstrated promising antitumor activity and acceptable safety profiles in clinical trials involving postmenopausal patients with HR+/HER2- advanced or early-stage breast cancer. Dalpiciclib plus letrozole is being studied both as neoadjuvant and first-line therapy. Adebrelimab's addition would theoretically provide immunotherapy benefit via PD-L1 blockade, though specific clinical trial data on this triple combination are not present in the provided search results.